Kahimmune Therapeutics partnered with Gustave Roussy to use patient samples from treated individuals to generate neoantigen data for Kahimmune’s first mRNA therapeutic candidate. The collaboration centers on identifying tumor-specific antigens, called “Kahigens,” using Kahimmune’s Kahinomics immunopeptidomics and bioinformatics platform. Kahimmune said it will aim to select antigens by mid-2027 and begin preclinical development of KAH-001, a lipid nanoparticle-based mRNA therapy candidate, in colorectal and pancreatic cancers by mid-2029. The project is supported by a €90,000 grant from France 2030 and Bpifrance, plus a €100,000 seed funding loan for platform development. The agreement underscores how early-stage mRNA oncology developers are building translational datasets directly from specialty cancer centers to sharpen target selection before major preclinical and regulatory milestones.